LLY - Amphastar a new overweight at J.P. Morgan on diverse asset portfolio
2024-03-05 14:42:07 ET
More on Amphastar Pharmaceuticals
- Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions
- Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript
- A First Look At Amphastar Pharmaceuticals
- Amphastar Pharmaceuticals Q4 2023 Earnings Preview
- Seeking Alpha’s Quant Rating on Amphastar Pharmaceuticals